Fundz

Hedge Path Pharmaceuticals, Inc. reported raising $600,000 in an initial SEC Form D filing, from an offering of $5.5 Million

PUBLIC · INTIApr 22, 2016$600K of $5.5M raised

Amount Raised

$600,000

$600,000 sold, per SEC Form D (first sale Apr 22, 2016)

Round Type

Seed

TampaBiotechnologyHealthcareHealth CareMedicalTherapeuticspharmaceuticals

Quick answer

Inhibitor Therapeutics raised $600,000 in a Seed round, dated April 22, 2016. Inhibitor Therapeutics is based in Tampa, Florida, United States.

How much did Inhibitor Therapeutics raise?
Inhibitor Therapeutics raised $600,000 in a Seed round on April 22, 2016.
What does Inhibitor Therapeutics do?
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration.
Where is Inhibitor Therapeutics based and how big is it?
Inhibitor Therapeutics is based in Tampa, Florida, United States. Fundz records about 3 employees.

Source: Fundz verified event record.

Who else raised in Healthcare and Medical around the same time

Companies in the same sectors as Inhibitor Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • ExThera Medical raised $15M on May 11, 2016.
  • ExThera Medical raised $6.7M on May 11, 2016.
  • ExThera Medical raised $12M on May 11, 2016.
  • CytoDyn raised $4.3M (Seed) on May 11, 2016.
  • TuHURA Biosciences raised $5.6M on May 10, 2016.
  • AbbVie Inc. raised $3.8B on May 9, 2016.

Who to call at Inhibitor Therapeutics, and when

A new round usually means Inhibitor Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Inhibitor Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inhibitor Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inhibitor Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Inhibitor Therapeutics

Location

4830 W Kennedy Blvd

Tampa, Florida, United States

About

Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons to form a Scientific Advisory Board (SAB) to critically review the outcomes of Inhibitor's phase 2b trial in BCCNS. They are academically affiliated, well-respected leaders in the practice of treating basal cell carcinomas and other skin cancers The purpose of the SAB is to assess the clinical benefits of adding itraconazole to the therapeutic options for the basal cell carcinomas in these patients. Dr. Sean R. Christensen, MD, PhD. is an Associate Professor of Dermatology; Director of Resident Education in Dermatologic Surgery; Director of Dermatologic Surgery at Yale Dermatology-Branford. Dr. Christensen has been practicing dermatologic surgery since completing training in 2013. His surgical specialization includes Mohs surgery, treatment of early-stage melanoma, and surgical reconstruction. Additionally, Dr. Christensen focuses on complex skin cancer issues such as field characterization, preventative strategies in high-risk patients and management of advanced or aggressive skin cancer. Dr. Christensen has published extensively on skin cancer pathogenesis and treatment and has experience in clinical trials for basal cell carcinoma. He is a frequent lecturer at national meetings for organizations such as the American Academy of Dermatology and the American College of Mohs surgery, and currently serves as the Treasurer for the International Transplant Skin Cancer Collaborative. For more information about Inhibitor and our mission please visit us on our website (www.inhibitortx.com)  and for any further or specific queries you may have please visit our contact us page, submit your details/query, and a representative will be happy to get in touch.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Inhibitor Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Inhibitor Therapeutics's next move

See what Strategic adds

Inhibitor Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.